Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

17:24 EDT 31st October 2014 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 27,000+

Friday 31st October 2014

Auspex begins Phase III AIM-TD trial of SD-809 in patients with tardive dyskinesia

Auspex Pharmaceuticals has started patient enrollment in a multi-center Phase III clinical trial of its investigational drug SD-809 (deutetrabenazine) to treat people with tardive dyskinesia, a debilitating and often irreversible movement disorder.

Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014

MENLO PARK, Calif., Oct. 31, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 10, 2014 after the close of the U.S. financial markets. The Company will host a conference call via webcast on Mon...

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call

CARLSBAD, Calif., Oct. 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:   What: Isis Pharmaceuticals' Third Quarter 2014 Financial Results and Highlights Conference Call When: Friday, November 7 at 11:30 a.m. ET / 8:30 a.m. PT

Generic Drugs May Help Breast Cancer Patients Stick to Therapy

FRIDAY, Oct. 31, 2014 (HealthDay News) -- Access to generic hormone therapy medicines improves the chances that breast cancer patients will stick with their drug treatment, a new study found. "We know that hormone therapy for women with hormone rece...

CE-Classes.com Celebrates Reaching 15,000 Customers

Approved online continuing education company announces that 15,000 customers have signed up on their website. Miami, FL (PRWEB) October 31, 2014 CE-Classes.com is celebrating a significant milestone as the company has recently reached 15,000 registrations. This South Florida-based company offers a broad range of Continuing Education (CE) courses that are specially designed to meet the needs of it...

Deep Raw Cashew Pieces by Chetak New York: AttorneyOne Monitors and Keeps Consumers Informed

On October 27, Chetak New York LLC announced the recall of 5560 packages of 7oz., 3840 packages of 14oz., & 1920 packages of 28oz. “Deep Raw Cashew Pieces” because of possible health risk. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) October 31, 2014 AttorneyOne.com, a recognized a...

Three Reasons to Adopt Unit-Level Traceability Now

David DeJea | Systech Pharmaceutical manufacturers and packagers are sprinting to build out their serialization architectures to comply with the Drug Supply Chain and Safety Act (DSCSA) requirements. It’s a race some will finish before others, and one in which some might not reach the finish line at all. While DSCSA compliance requirements may be […]

RetroSense gets FDA orphan drug status for RST-001 to treat retinitis pigmentosa

US-based RetroSense Therapeutics has received orphan drug designation from the Food and Drug Administration (FDA) for its lead product RST-001 to treat retinitis pigmentosa (RP), a genetic condition which leads to the progressive degeneration of rod ...

Insilico Medicine, CCARL and Plantbiosis partner to advance research on aging

Through this unique partnership, the Baltimore-based Insilico Medicine and Lethbridge-based CCARL will provide expertise in aging research and build on the personalized medicine and drug discovery platforms OncoFinder and GeroScope to develop new sys...

International GPCR Consortium Includes China Academic Members

The GPCR Consortium, a new not-for-profit effort, will seek to characterize the structure of 200 G-protein coupled receptors. Although GPCRs often serve as drug targets, they remain poorly understood, especially in terms of their structure. The Conso...

Xcovery Presents Phase 1 Results of X-396 in ALK positive NSCLC at the 2014 Multidisciplinary Symposium in Thoracic Oncology

–Induces responses in both crizotinib-naïve and crizotinib-resistant ALK+ NSCLC patients– -X-396 demonstrates activity in central nervous system metastases- Xcovery, a developer of next-generation targeted therapeutics for cancer, presented results at the

Thursday 30th October 2014

Ghrelin Stimulates Appetite For Drinking Alcohol

Provided by Rhiannon Bugno, Elsevier Editorial Office Ghrelin is a hormone released by the stomach and it stimulates appetite and food intake. Alcohol is commonly viewed as a psychoactive substance that primarily affects brain function, but it is also a highly caloric food. This knowledge, combined with findings from animal studies, led researchers to the hypothesis that ghrelin has the potentia...

Monthly News Roundup - October 2014

AstraZenenca’s Xigduo XR Approved for Type 2 Diabetes Type 2 diabetes is estimated to affect 29.1 million people in America. The U.S. Food and Drug Administration (FDA) has approved once-daily Xigduo XR (dapagliflozin and metformin...

Drug combination can trigger self-destruct process in lung cancer cells

Cancer Research UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells - paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute Ca...

Medical News Today: Surviving or dying from Ebola may be partly down to genes

Researchers studying mice with Ebola suggest the severity of reactions to the virus could be due to genetic factors and hope their work will help drug and vaccine development.

FDA panel backs Daiichi Sankyo's anti-stroke drug edoxaban

But it was the caveats that came with that vote the FDA will now have to wrangle with in determining the appropriate patient population and labeling for the drug.

Scientists trigger self-destruct switch in lung cancer cells

Cancer Research UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells – paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute...

CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014

NEWARK, CA--(Marketwired - October 31, 2014) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, November 12 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the Company's financial results for the quarter ended September 30, 2014 and to provide a general business update. Conference Call Details To acc...

Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014

LYON, FRANCE -- (Marketwired) -- 10/31/14 -- Flamel Technologies (NASDAQ: FLML) today announced its financial results for the third quarter of fiscal year 2014. Highlights from the quarter include: "We are very pleased that both Bloxiverz® and Vazculep™ are now available to hospital pharmacists, GPOs and distributors. As we believe that the unapproved versions of neostigmine inventory are bein...

Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders

BEVERLY, MA -- (Marketwired) -- 10/31/14 -- Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antibiotic applications, is pleased to provide a strategic and operations update to shareholders from the Company's newly appointed Chief Operating Officer, Dr. James Alexander. Cellceutix disclo...

Easton Launches www.EcigMarkets.com Ahead of Schedule and Commences Distributorship of Snoop Dog's Product Lines

TORONTO, ON -- (Marketwired) -- 10/31/14 -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has launched www.ecigmarkets.com ahead of schedule and commences distributorship of Snoop Dog's product lines. On October 7th Easton Pharmaceuticals announced its entry into the Vaporizer, Glassware and E Liquid sector as a complement to its Medical Marijuana initiatives. On October 22 Easton hired ...

AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approval

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes.

Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B disease

US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults.

Pfizer's Phase IV trial of sexual dysfunction drug Pristiq meets primary end point

Pfizer has reported positive results from its Phase IV clinical trial of Pristiq (desvenlafaxine) to treat sexual dysfunction in adult patients with major depressive disorder (MDD).

Study Finds Differences in Alcoholism Risk Among Hispanic Community

Harbor Village Florida comments on study finding differences in alcoholism risk among Hispanic community USA (PRWEB) October 30, 2014 As reported by the Latin Times in the article Hispanic Drinking Habits: New Study on Alcoholism Highlights Why Racial Category is Too Diverse to Group (10/21), a recent study on alcoholism and Hispanics has revealed some interesting findings. The study, completed ...

Search BioPortfolio:

News Quicklinks